Crispr Therapeutics Ag Stock Buy Hold or Sell Recommendation
| CRSP Stock | USD 36.99 1.05 2.76% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Crispr Therapeutics AG is 'Hold'. A buy or sell recommendation provided by Macroaxis is an automated analysis based on historical performance and your stated risk tolerance. It serves as guidance on whether to purchase or sell Crispr Therapeutics AG within the specified time frame.
Check out Crispr Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Crispr and provide practical buy, sell, or hold advice based on investors' constraints. Crispr Therapeutics AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
Crispr |
Execute Crispr Therapeutics Buy or Sell Advice
The Crispr recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Crispr Therapeutics AG. Macroaxis does not own or have any residual interests in Crispr Therapeutics AG or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Crispr Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
30 Days |
Risk Tolerance
I am an educated risk taker |
 |  |
Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Crispr Therapeutics Trading Alerts and Improvement Suggestions
| Crispr Therapeutics generated a negative expected return over the last 90 days | |
| Crispr Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 35 M. Net Loss for the year was (366.25 M) with loss before overhead, payroll, taxes, and interest of (393.59 M). | |
| Crispr Therapeutics AG currently holds about 2.07 B in cash with (142.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 26.48. | |
| Crispr Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 78.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from phys.org: New light-controlled CRISPR tool enhances precision in genetic research |
Crispr Therapeutics Returns Distribution Density
The distribution of Crispr Therapeutics' historical returns is an attempt to chart the uncertainty of Crispr Therapeutics' future price movements. The chart of the probability distribution of Crispr Therapeutics daily returns describes the distribution of returns around its average expected value. We use Crispr Therapeutics AG price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Crispr Therapeutics returns is essential to provide solid investment advice for Crispr Therapeutics.
| Mean Return | -0.09 |
| Value At Risk | -4.42 |
| Potential Upside | 5.26 |
| Standard Deviation | 3.54 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Crispr Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Crispr Stock Institutional Investors
The Crispr Therapeutics' institutional investors refer to entities that pool money to purchase Crispr Therapeutics' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | |||
| Orbis Allan Gray Ltd | 2024-12-31 | 1.5 M | |
| Ecor1 Capital, Llc | 2024-12-31 | 1.4 M | |
| Baker Bros Advisors Lp | 2024-12-31 | 1.3 M | |
| Bank Of America Corp | 2024-12-31 | 1.2 M | |
| Sr One Capital Management, Lp | 2024-12-31 | 1 M | |
| Geode Capital Management, Llc | 2024-12-31 | 1 M | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 947.3 K | |
| Loomis, Sayles & Company Lp | 2024-12-31 | 911 K | |
| Balyasny Asset Management Llc | 2024-12-31 | 893.9 K | |
| Ark Investment Management Llc | 2024-12-31 | 9 M | |
| Capital Research & Mgmt Co - Division 3 | 2024-12-31 | 8.7 M |
Crispr Therapeutics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Investments | (522.8M) | (953.7M) | (258.7M) | 280.6M | (280.5M) | (266.5M) | |
| Change In Cash | 236.7M | (245.5M) | (715.9M) | 177.0M | (91.3M) | (86.7M) | |
| Free Cash Flow | (256.7M) | 457.3M | (532.9M) | (272.3M) | (144.7M) | (137.4M) | |
| Depreciation | 9.2M | 18.0M | 24.2M | 19.8M | 19.3M | 10.3M | |
| Other Non Cash Items | 1.9M | 14.1M | 12.5M | (14.0M) | (38.6M) | (36.7M) | |
| Capital Expenditures | 18.4M | 81.7M | 37.2M | 12.0M | 1.9M | 1.8M | |
| Net Income | (348.9M) | 377.7M | (650.2M) | (153.6M) | (366.3M) | (347.9M) | |
| End Period Cash Flow | 1.2B | 939.9M | 224.1M | 401.1M | 309.8M | 518.1M | |
| Change To Netincome | 49.5M | 67.9M | 102.4M | 110.4M | 127.0M | 133.3M | |
| Change To Inventory | (5.0M) | (25.7M) | (37.5M) | 23.3M | 26.8M | 28.2M | |
| Change Receivables | (11K) | (45K) | (161K) | 305K | 350.8K | 368.3K |
Crispr Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Crispr Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Crispr Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Crispr stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.02 | |
β | Beta against Dow Jones | 1.39 | |
σ | Overall volatility | 3.64 | |
Ir | Information ratio | -0.01 |
Crispr Therapeutics Volatility Alert
Crispr Therapeutics AG exhibits very low volatility with skewness of 1.34 and kurtosis of 3.3. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Crispr Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Crispr Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Crispr Therapeutics Fundamentals Vs Peers
Comparing Crispr Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Crispr Therapeutics' direct or indirect competition across all of the common fundamentals between Crispr Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Crispr Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Crispr Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Crispr Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Crispr Therapeutics to competition |
| Fundamentals | Crispr Therapeutics | Peer Average |
| Return On Equity | -0.19 | -0.31 |
| Return On Asset | -0.13 | -0.14 |
| Operating Margin | (1.81) % | (5.51) % |
| Current Valuation | 1.49 B | 16.62 B |
| Shares Outstanding | 85.77 M | 571.82 M |
| Shares Owned By Insiders | 1.67 % | 10.09 % |
| Shares Owned By Institutions | 77.74 % | 39.21 % |
| Number Of Shares Shorted | 20.41 M | 4.71 M |
| Price To Earning | 17.33 X | 28.72 X |
| Price To Book | 1.64 X | 9.51 X |
| Price To Sales | 85.03 X | 11.42 X |
| Revenue | 35 M | 9.43 B |
| Gross Profit | (393.59 M) | 27.38 B |
| EBITDA | (466.57 M) | 3.9 B |
| Net Income | (366.25 M) | 570.98 M |
| Cash And Equivalents | 2.07 B | 2.7 B |
| Cash Per Share | 26.48 X | 5.01 X |
| Total Debt | 223.69 M | 5.32 B |
| Debt To Equity | 0.12 % | 48.70 % |
| Current Ratio | 17.57 X | 2.16 X |
| Book Value Per Share | 22.53 X | 1.93 K |
| Cash Flow From Operations | (142.77 M) | 971.22 M |
| Short Ratio | 8.11 X | 4.00 X |
| Earnings Per Share | (4.34) X | 3.12 X |
| Price To Earnings To Growth | (0.21) X | 4.89 X |
| Target Price | 83.6 | |
| Number Of Employees | 393 | 18.84 K |
| Beta | 1.76 | -0.15 |
| Market Capitalization | 3.17 B | 19.03 B |
| Total Asset | 2.24 B | 29.47 B |
| Retained Earnings | (1.37 B) | 9.33 B |
| Working Capital | 1.85 B | 1.48 B |
| Current Asset | 232 M | 9.34 B |
Note: Disposition of 190 shares by Bruno Julianne of Crispr Therapeutics at 43.32 subject to Rule 16b-3 [view details]
Crispr Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Crispr . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 53215.53 | |||
| Daily Balance Of Power | (0.83) | |||
| Rate Of Daily Change | 0.97 | |||
| Day Median Price | 37.57 | |||
| Day Typical Price | 37.37 | |||
| Price Action Indicator | (1.10) | |||
| Period Momentum Indicator | (1.05) | |||
| Relative Strength Index | 50.06 |
About Crispr Therapeutics Buy or Sell Advice
When is the right time to buy or sell Crispr Therapeutics AG? Buying financial instruments such as Crispr Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Crispr Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Investing Thematic Idea Now
Investing
Companies involved in money management and investment banking services. The Investing theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Investing Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Crispr Stock Analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.